about
Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy.Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimenInduction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in childrenSex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.Absence seizures associated with efavirenz initiationCase report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed.Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialEfavirenz is associated with higher bone mass in South African children with HIV.Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical TrialAdherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virusDecreased Vigorous Physical Activity in School-Aged Children with Human Immunodeficiency Virus in Johannesburg, South Africa.Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected ChildrenBenefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status.Timing of maternal HIV testing and uptake of prevention of mother-to-child transmission interventions among women and their infected infants in Johannesburg, South Africa.Unusually High Calcaneal Speed of Sound Measurements in Children with Small Foot Size.Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study.Prevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing - an urban South African observational cohort.Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.Dietary Inadequacies in HIV-infected and Uninfected School-aged Children in Johannesburg, South Africa.Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants.Reply to van de Wijer et. al.Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children.Neurodevelopmental assessment of HIV-exposed uninfected and early-treated HIV-infected children: study protocol.Decreased bone turnover in HIV-infected children on antiretroviral therapy.Benefits and Risks of Antiretroviral Therapy for Perinatal HIV PreventionBiomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral TherapyAbacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavirA description of early neurodevelopment in a cohort of HIV-exposed uninfected children
P50
Q33605245-DAA750DE-E198-4F76-872B-6A56488B6500Q34112568-C08BDDBD-7C67-48D8-AE82-541FFC25F5C7Q34159649-ACDED850-E599-4145-BF60-C2AFA50A145BQ34498914-C3A31B02-372B-42FB-9BFB-7D8BBC6D388CQ34699162-C1A2D9FE-EA12-48D1-BB55-1D716583900BQ35093189-ED320DD8-B06C-415D-B0CC-5E399B529A68Q35179391-0DD6449F-87D7-4561-A49F-0AF6D857345DQ35722000-984293E7-E0BC-437C-9FD3-9D8DAB1E4CA9Q35752638-A25FE7DE-0868-47B7-98BB-0B3ED2A35235Q35910664-F6FBD1BA-4CC5-477E-A199-7A9B853AE5D3Q35926011-B71B77C5-A8BC-48E3-A480-9FC3F4D2E08BQ35942373-D05B60F2-CC18-4DF8-897B-A1722D8C45ADQ35945312-E75F371F-BA7B-4FF3-AD4D-690CFAFA95E3Q35962423-7BF9FCAB-2324-49CC-B3F9-90EFB0DEEBDBQ35965440-FDEC8292-968C-47E2-95A9-53604CDC199EQ36079798-E1320B9C-1DAF-4A4B-83A3-13E97A4476B7Q36306986-C128C891-F593-434E-9801-0BDFB14180A5Q36759507-52D634A0-09EA-45CB-B18A-ECAEA2A56CCBQ36807963-BA5F9B3C-B05F-406E-B182-E4E1657F34B0Q36839977-3EC149A3-BD51-4805-B71F-241671699316Q37029110-7BE8A392-4549-4692-B30C-B3D55BFE8A47Q37513856-68F8F877-D491-4DBD-A628-8C6BF7F2F474Q37558394-2E0199F6-1DF1-41C8-9485-572AC72FDD44Q37653305-9664D747-73CC-40D4-BA52-DA8007D6BEFFQ37723043-BF13C58B-94F9-4046-86A1-7EF9FBCEF661Q38410244-241DBDFF-1259-4924-9B1D-7F1A513C5336Q38798094-E6031CA5-E278-468D-A0B5-53BDBFE6D9F5Q40057847-9BDFBC12-6C16-4223-8CDF-3D8E9AF5A33AQ40238381-27C15567-C4A1-4B3B-B35F-2CAD06C44D2AQ40278259-29956C66-482B-4FBA-83EC-7D5051B6952AQ40458484-6D3280F1-0CC3-4C0D-9276-C5482FCB5EA4Q46699168-43344458-0BD2-473E-B053-A67FACF71A1BQ47548671-EE13547E-1024-4738-8733-F2EBC8AC2061Q52591828-DB850050-9950-44B8-B577-EE8E97C5278FQ52602006-4AFAFBA1-C7C7-42CD-8544-1DE01450E994Q52603395-2041B94D-9C4C-40AD-A402-D6D068844381Q57207477-74C6DCCA-3264-47FF-AA86-13CF62CBBB60Q88715164-0A06C977-5D6C-4D2F-8B9E-6DF0FAB8F676Q89766014-06C2897D-CBC6-44CB-92A7-7040E760918EQ89980044-53D02EC4-79D1-4555-8519-FE0BF577BA40
P50
description
researcher
@en
wetenschapper
@nl
name
Renate Strehlau
@en
Renate Strehlau
@nl
type
label
Renate Strehlau
@en
Renate Strehlau
@nl
prefLabel
Renate Strehlau
@en
Renate Strehlau
@nl
P31
P496
0000-0001-9113-6584